Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-01-01 Epub Date: 2024-07-26 DOI:10.1080/14796694.2024.2375959

Oppah Kuguyo, Alice Matimba, Mugove G Madziyire, Thulani Magwali, Collet Dandara, Charles Fb Nhachi, Nomsa Tsikai

{"title":"Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer.","authors":"Oppah Kuguyo, Alice Matimba, Mugove G Madziyire, Thulani Magwali, Collet Dandara, Charles Fb Nhachi, Nomsa Tsikai","doi":"10.1080/14796694.2024.2375959","DOIUrl":null,"url":null,"abstract":"Aim: To describe treatment-induced toxicities (TITs) and associated factors in Zimbabwean cancer patients receiving cisplatin.Methods: In total, 252 Zimbabwean women with cervical cancer, receiving cisplatin were followed up over 12 months for TITs and disease status.Results: Peripheral neuropathy (70%) and ototoxicity (53%) were most prevalent. Advanced disease (OR = 1.3; 95% CI = 1.1-1.5; p = 0.02), pain comedications (OR = 1.3; 95% CI = 1.1-1.5; p = 0.03), alcohol (OR = 2.8; 95% CI = 1.1-7.5; p = 0.04) and comorbidities (OR = 1.2; 95% CI = 1.1-1.4; p = 0.04) increased peripheral neuropathy and ototoxicity risk. Older age increased risk of disease progression (OR = 1.9; 95% CI = 1.4-3.0; p = 0.033).Conclusion: High peripheral neuropathy and ototoxicity prevalence were observed, which are not routinely monitored in Zimbabwe. There is a need for capacity building to incorporate comprehensive TIT testing and optimize cancer care in Zimbabwe.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498005/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2375959","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To describe treatment-induced toxicities (TITs) and associated factors in Zimbabwean cancer patients receiving cisplatin.Methods: In total, 252 Zimbabwean women with cervical cancer, receiving cisplatin were followed up over 12 months for TITs and disease status.Results: Peripheral neuropathy (70%) and ototoxicity (53%) were most prevalent. Advanced disease (OR = 1.3; 95% CI = 1.1-1.5; p = 0.02), pain comedications (OR = 1.3; 95% CI = 1.1-1.5; p = 0.03), alcohol (OR = 2.8; 95% CI = 1.1-7.5; p = 0.04) and comorbidities (OR = 1.2; 95% CI = 1.1-1.4; p = 0.04) increased peripheral neuropathy and ototoxicity risk. Older age increased risk of disease progression (OR = 1.9; 95% CI = 1.4-3.0; p = 0.033).Conclusion: High peripheral neuropathy and ototoxicity prevalence were observed, which are not routinely monitored in Zimbabwe. There is a need for capacity building to incorporate comprehensive TIT testing and optimize cancer care in Zimbabwe.

查看原文本刊更多论文

津巴布韦宫颈癌妇女中顺铂引起的毒性反应的发生率和预测因素。

目的：描述接受顺铂治疗的津巴布韦癌症患者的治疗诱发毒性（TITs）及相关因素。方法共对 252 名接受顺铂治疗的津巴布韦宫颈癌妇女进行了为期 12 个月的随访，以了解 TITs 和疾病状况。结果外周神经病变（70%）和耳毒性（53%）最为常见。晚期疾病（OR = 1.3；95% CI = 1.1-1.5；p = 0.02）、止痛药物（OR = 1.3；95% CI = 1.1-1.5；p = 0.03）、酒精（OR = 2.8；95% CI = 1.1-7.5；p = 0.04）和合并症（OR = 1.2；95% CI = 1.1-1.4；p = 0.04）增加了周围神经病变和耳毒性的风险。年龄越大，疾病进展风险越高（OR = 1.9；95% CI = 1.4-3.0；p = 0.033）。结论观察到外周神经病变和耳毒性发病率较高，而津巴布韦并未对其进行常规监测。津巴布韦需要进行能力建设，以纳入全面的 TIT 检测并优化癌症护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.